Clinical trials referenced in this document:
Documents that mention this clinical trial
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial
https://doi.org/10.1007/s11060-018-03057-z
Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
https://doi.org/10.1007/s11060-019-03361-2
Funding for this research was provided by:
Novocure
Article History
Received: 30 August 2018
Accepted: 21 November 2018
First Online: 1 December 2018
Compliance with ethical standards
:
: S. A. Toms, C. Y. Kim and G. Nicholas have nothing to disclose. Z. Ram reports a research grant (principal investigator and consultant) with Novocure, Ltd. and ownership interest (stock) in Novocure, Ltd.